“Revision of Affordable Act during 2013, higher registrations through Medicaid & Medicare as well as Investment by private insurance players to drive investment in US Generics industry”, says RNCOS.
Noida, UP -- (SBWIRE) -- 05/04/2015 -- According to a new research report by RNCOS entitled, "US Generic Drug Market Outlook 2018", the United States devotes highest expenditure on healthcare as compared to any other Country globally. The US provides more health care in terms of more doctors' appointments, more surgery, more drugs, more diagnostic tests, longer stays in hospital than other countries. The region has considerably increased its healthcare expenditure from US$ 2,414 Billion to US$ 2,919 Billion in 2013. National Health expenditure in the US can be segmented as services provided by private sector and Government (public) share.
Among the public services Affordable Care Act has been providing sufficient insurance to the Americans. The Obama Administration had estimated that about 7 Million people would enroll in exchanges in 2014, of which about 5 Million would represent newly insured persons. Medicaid and Medicare are two governmental programs that provide medical and health-related services to specific groups of people (low income group and people with limited resources). Over the years, share of private sector has increased as compared to the public sharing. Insurance companies have significantly shifted costs from patients through high-deductible plans and other measures, prompting Americans to limit visits to doctors and hospitals.
The report is spread in over 100 pages and provides an in-depth research and rational analysis of the current status and future prospect of the US Generics industry. The report provides clear picture of Generics market, its growth, and drivers & challenges. In addition to this, the study further highlights emerging trends and developments which have been occurring in the US over the years, market potential of Generics in key therapeutic segments, competitive landscape and regulatory scenario, among other pointers. It also provides valuable information to pharmaceutical and generic drug companies and investors looking to enter in this market. Facts and figures regarding market size, growth, share, regulatory environment and trends in technology development have been thoroughly analyzed in the report to provide clients a comprehensive overview of the market.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM731.htm
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
About RNCOS
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.